



JFW

Patent Application
Attorney Docket No. PC27401A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 12 day of May, 2005.

By Erica L. Smith
(Signature of person mailing)
Erica L. Smith
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jerry R. Colca, et al. :

APPLICATION NO.: 10/728,679 : Examiner:

FILING DATE: December 5, 2003 : Group Art Unit:

TITLE: MitoNEET Polypeptide from Introchondrial :
Membranes, Modulators Thereof, and Methods of
Using the Same

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: 5/9/05
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0041

Respectfully submitted,
Gabriel L. Kleiman
Gabriel L. Kleiman
Attorney for Applicant(s)
Reg. No. 40,861

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								ATTY. DOCKET NO. PC27401A				SERIAL NO. 10/728,679							
								APPLICANT Jerry R. Colca, et al.											
								FILING DATE December 5, 2003				GROUP							
U.S. PATENT DOCUMENTS																			
EXAMINEE INITIAL		DOCUMENT NUMBER								DATE		NAME		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER										DATE		COUNTRY		CLASS		SUBCLASS		TRANSLATION	
																		YES NO	
	WO	9	4	2	5	0	2	6	11/10/94	International		A61K		31/42					
	WO	0	2	4	3	7	1	6	6/6/02	International		A61K		31/00					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
			Burant, et al., <u>Journal of Clinical Investigations</u> , "Troglitazone Action Is Independent of Adipose Tissue", Vol. 100, pages 2900-2908 (1997)																
			Chang, et al., <u>Diabetes</u> , "Ciglitazone, a n-New Hypoglycemic Agent. II. Effect on Glucose and Lipid Metabolisms and Insulin Binding in the Adipose Tissue of C57BL/6J-ob/ob and -+/? Mice", Vol. 32, pages 839-845 (1983)																
			Colca, et al., <u>New Antidiabetic Drugs</u> , "Antihyperglycaemic Thiazolidinediones: ciglitazone and Its Analogues", pages 255-261 (1990)																
			Dreyer, et al., <u>Cell</u> , "Control of the Peroxisomal β -oxidation Pathway by a Novel Family of Nuclear Hormone Receptors", Vol. 68, pages 879-887 (1992)																
			Goeke, R., et al., <u>Digestion</u> , "Pioglitazone Inhibits Growth of Carcinoid Cells and promotes TRAIL-Induced Apoptosis by Induction of p21 ^{waf1/cip1} ", Vol. 64, pages 75-80 (2001)																
			Gottlicher, <u>Proceedings of the National Academy of Science</u> , "Fatty Acids Activate a Chimera of the Clofibrilic Acid-Activated Receptor and the Glucocorticoid Receptor", Vol. 89, pages 4653-4657 (1992)																
			Harris, et al., <u>Molecular Pharmacology</u> , "Localization of a Pioglitazone Response Element in the Adipocyte Fatty Acid-Binding Protein Gene", Vol. 45, pages 439-445 (1994)																

<p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>MAY 12 2005</p>		<p>ATTY. DOCKET NO. PC27401A</p>	<p>SERIAL NO. 10/728,679</p>
<p>APPLICANT Jerry R. Colca, et al.</p>		<p>FILING DATE December 5, 2003</p>	
<p>GROUP</p>			

			<p>Hiragun, et al., <u>Journal of Cell Physiology</u>, "Preadipocyte Differentiation in Vitro: Identification of a Highly Active Adipogenic Agent", Vol. 134, pages 124-130 (1988)</p>
			<p>Isseman, et al., <u>Nature</u>, "Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators", Vol. 347, pages 645-650 (1990)</p>
			<p>Itami, A., et al., <u>International Journal of Cancer</u>, "Ligands for Peroxisome Proliferator-Activated Receptor γ Inhibit Growth of Pancreatic Cancers both in Vitro and In Vivo", Vol. 94, pages 370-376 (2001)</p>
			<p>Keller, et al., <u>Trends Endocrinology Metabolism</u>, "Peroxisome Proliferator-Activated Receptors A Link Between Endocrinology and Nutrition?", Vol. 4, pages 291-296 (1993)</p>
			<p>Kletzien, et al., <u>Molecular Pharmacology</u>, "Enhancement of Adipocyte Differentiation by an Insulin-Sensitizing Agent", Vol. 41, pages 393-398 (1992)</p>
			<p>Kliwer, et al., <u>Proceedings of National Academy of Science</u>, "Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-Activated Receptors", Vol. 91, pages 7355-7359 (1994)</p>
			<p>Mueller, E., et al., <u>Molecular Cell</u>, "Terminal Differentiation of Human Breast Cancer through PPARγ", Vol. 1, pages 465-470 (1998)</p>
			<p>Nolan, et al., <u>New England Journal of Medicine</u>, "Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone", Vol. 331, pages 1188-1193 (1994)</p>
			<p>Okano, H., et al., <u>Anti-Cancer Drugs</u>, "Peroxisome Proliferator-Activated Receptor γ Augments Tumor Necrosis Factor Family-Induced Apoptosis in Hepatocellular Carcinoma", Vol. 13, pages 59-65 (2002)</p>
			<p>Sparks, et al., <u>Journal of Cell Physiology</u>, "Antidiabetic AD4743 Enhances Adipocyte Differentiation of 3T3 T Mesenchymal Stem Cells", Vol. 146, pages 101-109 (1991)</p>
			<p>Tanaka, T., et al., <u>Cancer Research</u>, "Ligands for Peroxisome Proliferator-activated Receptors α and γ Inhibit Chemically Induced Colitis and Formation of Aberrant Crypt Foci in Rats¹", Vol. 61, pages 2424-2428 (2001)</p>
			<p>Tontonoz, et al., <u>Genes and Development</u>, "mPPAR gamma 2: Tissue-Specific Regulator of an Adipocyte Enhancer", Vol. 8, pages 1224-1234 (1994)</p>
			<p>Williams, et al., <u>Diabetes</u>, Vol. 42, Supplement 1, page 59A (1993)</p>
			<p>Zhu, et al., <u>Journal of Biological Chemistry</u>, "Cloning of a New Member of the Peroxisome Proliferator-Activated Receptor Gene Family from Mouse Liver", Vol. 268, pages 26817-26820 (1993)</p>

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.